{"id":324926,"date":"2025-08-07T10:22:12","date_gmt":"2025-08-07T10:22:12","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/324926\/"},"modified":"2025-08-07T10:22:12","modified_gmt":"2025-08-07T10:22:12","slug":"new-review-highlights-untapped-potential-of-the-vaginal-microbiome-in-womens-health","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/324926\/","title":{"rendered":"New review highlights untapped potential of the vaginal microbiome in women\u2019s health"},"content":{"rendered":"

The vaginal microbiome is a largely overlooked area of medicine that could dramatically improve outcomes for millions of women, concludes a new review<\/a> co-authored by the Medicine and Healthcare products Regulatory Agency (MHRA) published today (7 August).\u00a0<\/p>\n

Vaginal microbiome testing has the potential to revolutionise women\u2019s health by enabling earlier, more accurate, and more personalised diagnosis and treatment of a wide range of conditions \u2013 such as common infections, infertility and even cancer.\u00a0<\/p>\n

The MHRA worked with researchers at Kings College Hospital London, the University of Liverpool, Ewha Women\u2019s University and Biowave W Seoul to explore the significant potential of vaginal microbiome diagnostics to revolutionise how we detect, treat and manage a wide range of women\u2019s health conditions \u2013 including infertility, miscarriage, preterm birth, gynaecological cancers and menopause-related complications.\u00a0<\/p>\n

While the gut microbiome has received widespread attention over the last decade, research into the vaginal microbiome has lagged far behind. Nevertheless, this dynamic ecosystem of bacteria plays a critical role in supporting reproductive health and protecting against infection throughout a woman\u2019s life.\u00a0<\/p>\n

Dr Chrysi Sergaki, Head of Microbiome at the MHRA, said:\u00a0\u00a0<\/p>\n

\u201cWe are only beginning to understand how powerful the vaginal microbiome could be as a diagnostic tool. This review sets out the case for making this a major focus of women\u2019s health research and development going forward.\u201d\u00a0<\/p>\n

A case for change\u00a0<\/p>\n

Currently, many diagnostic tools in women\u2019s health are imprecise or subjective, leading to delays in diagnosis, preventative measures and treatment of diseases. The paper highlights how microbiome-based diagnostics could offer faster, more accurate, and personalised options to detect conditions like bacterial vaginosis (a common vaginal condition caused by an imbalance in the types of bacteria present in the vagina), sexually transmitted infections (STIs), endometriosis (a condition where tissue similar to the lining of the uterus (endometrium) grows outside the uterus, often in the pelvic area), and even fertility and pregnancy complications, including preterm birth).\u00a0<\/p>\n

The review also highlights the historic underrepresentation of women in clinical research, a gap that has contributed to critical shortcomings in our understanding of female-specific conditions. For example, a study shows that 86 randomised controlled trials in 9 journals show that women account for only 37% of participants in many clinical trials<\/a>, limiting the ability to fully assess how treatments perform in female patients, including their effectiveness and potential side effects. A recent analysis of the current clinical trial landscape in the UK<\/a> showed that male-only trials (6.1%) were nearly twice as common as female-only studies (3.7%).\u202f Pregnant and breastfeeding women were represented in 1.1% and 0.6% of trials, respectively, which could impact treatment suitability for these groups.\u00a0<\/p>\n

What the MHRA is doing to support microbiome-based testing\u00a0<\/p>\n

The MHRA is supporting scientists and companies in developing innovative microbiome-based tests, helping to accelerate growth in this emerging field. It is doing this by:\u00a0<\/p>\n